Ajovy[®] Prior Authorization Request Form (Page 1 of 2) DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY HAVE BARCODES.

This form may be faxed to 844-403-1029.

Member Information (required)				Provider Information (required)			
Member Name:			Provider Na	Provider Name:			
Insurance ID#:			NPI#:	NPI#: Specialty:			
Date of Birth:			Office Phone	Office Phone:			
Street Address:			Office Fax:	Office Fax:			
City:	State:	ZIP:	Office Stree	Office Street Address:			
Phone:			City:	State:	State: ZIF		
		Medicatio	n Informatior	(required)			
Medication Name:			Strength:	Dosage Form:		n:	
			Directions for	or Use:			
		Clinical	Information (required)			
Initial Authorization							
1. Does the patient have a diagnosis of episodic migraines?						□ Yes □ No	
2. Does the patient month?	have four to 14 mig	graine days per m	nonth, but no more	than 14 headache	adays per	🗆 Yes 🗆 No	
3. Does the patient have a diagnosis of chronic migraines?					🛛 Yes 🖵 No		
4. Does the patient have greater than or equal to 15 headache days per month, of which at least eight must be migraine days for at least three months?					🛛 Yes 🗆 No		
5. Has medication overuse headache been considered and have potentially offending medication(s) been discontinued?					🗆 Yes 🗆 No		
6. Does the patient have a history of failure (after at least a two-month trial) or intolerance to Elavil (amitriptyline) or Effexor (venlafaxine)?					🛛 Yes 🗆 No		
7. Does the patient have a contraindication to BOTH Elavil (amitriptyline) and Effexor (venlafaxine)?						🛛 Yes 🖵 No	
8. Does the patient have a history of failure (after at least a two-month trial) or intolerance to Depakote/Depakote ER (divalproex sodium) or Topamax (topiramate)?						🛛 Yes 🗅 No	
9. Does the patient have a contraindication to BOTH Depakote/Depakote ER (divalproex sodium) and Topamax (topiramate)?						🛛 Yes 🗆 No	
10. Does the patient have a history of failure (after at least a two-month trial) or intolerance to ONE of the following beta blockers: atenolol, propranolol, nadolol, timolol or metoprolol?						🛛 Yes 🗆 No	
11. Does the patient have a contraindication to ALL of the following beta blockers: atenolol, propranolol, nadolol, timolol and metoprolol?						🛛 Yes 🗆 No	
12. Has the patient had a trial and failure, contraindication, or intolerance to BOTH of the following: Aimovig and Emgality?						g 🛛 Yes 🗆 No	

This document - and others if attached - contains information that is privileged, confidential and/or may contain protected health information (PHI). The provider named above is required by applicable law to safeguard PHI. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately. Office use only: Ajovy_2020Feb

Ajovy[®] Prior Authorization Request Form (Page 2 of 2)

Reauthorization:		
 Has the patient experienced a positive response to therapy, demonstrated by a reduction in headache frequency and/or intensity? 	🛛 Yes 🖾 No	
2. Has the use of acute migraine medications (e.g., NSAIDs, triptans) decreased since the start of CGRP therapy?	🛛 Yes 🖾 No	
3. For chronic migraine, does the patient continue to be monitored for medication overuse headache (MOH)?		

Information on this form is accurate as of this date.

Prescriber's Signature:		Date:	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

<u>Please note</u>: **This request may be denied unless all required information is received.** For more information about the prior authorization process, please contact us at 855-811-2218. Monday – Friday: 8 a.m. to 1 a.m. Eastern, and Saturday: 9 a.m. to 6 p.m. Eastern

This document – and others if attached – contains information that is privileged, confidential and/or may contain protected health information (PHI). The provider named above is required by applicable law to safeguard PHI. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.** Office use only: Ajovy_2020Feb